UAE becomes second country to approve new treatment for Alzheimer’s disease

The United Arab Emirates became the second country in the world, after the United States, to approve the registration and use of Biogen’s Aduhelm (aducanumab), the first and only drug to treat the early stages of cancer. Alzheimer’s disease.

The drug is supplied in the form of injections containing a dose of 100 ml. It is prescribed for patients with early stages of Alzheimer’s disease (mild cognitive impairment and mild dementia) and helps reduce beta-amyloid plaques in the brain.

The efficacy of Aduhelm was evaluated in two phase 3 clinical trials EMERGE (study 1) and ENGAGE (study 2) in patients with early stages of Alzheimer’s disease with confirmed presence of amyloid disease. The effects of Aduhelm were also evaluated in the Phase 1b, double-blind, randomized, placebo-controlled, dose-finding study PRIME (Study 3).

“For the first time in history, we have achieved an unprecedented feat by going beyond treating the symptoms of Alzheimer’s disease to targeting its main causes. Early detection and diagnosis of MCI will allow us to identify patients who may benefit from this innovative treatment, ”said Dr. Paul Aisen, Alzheimer’s Therapeutic Research Institute (ATRI), University of Southern California.

Rachid Azar, Executive Vice President of the Alzheimer’s and Cognitive Impairments Business Unit, added: “Biogen’s tireless research efforts and dedication to achieving its goals have enabled us to fulfill our commitment to provide the first treatment of its kind. for many years to patients with Alzheimer’s disease. We believe that this drug will give patients with early-stage Alzheimer’s disease, their families and healthcare providers a new beacon of hope, especially as they await scientific advancements in this regard. regard for decades.

Abdul Rahman bin Mohammad bin Nasser Al Owais, Minister of Health and Prevention, highlighted MoHAP’s commitment to provide therapeutic and psychological services to people with Alzheimer’s disease, especially those over the age of 65 years old, because these are the high risk groups. These services include specialized clinics, providing a supportive and stimulating environment for patients, and community rehabilitation, according to the WAM news agency.

Aduhelm was previously approved by the Food and Drug Administration (FDA) in the United States, and its approval by the authorities of the United Arab Emirates complied with the Fast Track / Accelerate Process system of the Ministry of Health and Prevention (MoHAP).

Abdul Rahman bin Mohammad bin Nasser Al Owais, Minister of Health and Prevention, said the UAE is among the fastest countries in the world in terms of approval of innovative drugs. The ministry has an advanced drug authorization and registration mechanism in accordance with the best international standards and requirements for pharmacological evaluation, added Dr Amin Hussein Al Amiri, Deputy Under Secretary for the Regulatory Sector. of health. Dr Amin also noted that the ministry is proactively working to communicate with international drug and medical supply companies to learn about the latest medical innovations, even though they are in clinical studies, in order to bring them in the United Arab Emirates after approval by the United States. Food and Drug Administration (FDA).

The United Arab Emirates will open their first elderly care center in Dubai. The Vita Elderly Care Complex, located in Dubai Healthcare City, will provide services to Emirati elderly and expats over 65. When completed, the Vita Elderly Care Complex, with a capacity of 250 beds, will offer a range of services, including an outpatient geriatric medical center. , Advanced Nursing Home (Long Term Care), Alzheimer’s Center, Elderly Day Care Center, Rehabilitation Center, Ventilated Care Center, Home Care Center and Home Health Monitoring.

Read: UAE to create country’s first elderly care center in Dubai

Source link

About Hector Hedgepeth

Hector Hedgepeth

Check Also

Diadem presents data at 22nd International Alzheimer’s Drug Discovery Conference, emphasizing that his blood biomarker test is 84% ​​concordant with amyloid brain imaging

Further analysis of clinical validation data shows that Diadem’s AlzoSure® prediction is highly concordant with …

Leave a Reply

Your email address will not be published. Required fields are marked *